The Th2 cytokine inhibitor, suplatast tosilate 300mg/day was administered to 163 patients with atopic dermatitis who had been poorly controlled by other anti-allergic drugs. The usefulness of suplatast tosilate was evaluated witfi respect to skin symptom score and parameters such as IgE, eosinophil and basophil counts, and LDH. After 4 weeks of treatment, the skin symptom score, eosinophil counts and LDH were significantly decreased, whereas other parameters remained unchanged.
|Number of pages||7|
|Issue number||SUPPL. 8|
|Publication status||Published - Mar 1 2007|
All Science Journal Classification (ASJC) codes
- Infectious Diseases